Extavia

Selected form

Interferon Beta-1a

Method of action: Antitumour, Immunomodulating, Immunostimulants

Treatment option: Multiple Sclerosis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Extavia

Property	Description
Active ingredient	Interferon Beta-1b
Form	Lyophilized powder for solution for injection
Pharmacological class	Immunomodulator, Interferon
General purpose	Disease-Modifying Therapy (DMT)
Origin	Recombinant protein (produced in E. coli)

What Type of Medicine is Extavia?

Extavia is classified as a Disease-Modifying Therapy (DMT) and a Biological Response Modifier, belonging to the Interferon class of therapeutic proteins. The active substance is Interferon Beta-1b, a specialized protein used to modulate the body’s immune system, which makes it an Immunostimulant. This medicine is clinically recognized for its role in influencing the core immune response in adults.

Its designation as a DMT is fundamental, signifying the medication is intended to alter the underlying biological processes of a chronic condition, rather than simply treating isolated or acute symptoms. This purpose relates to how the medication interacts with the body's biological pathways.

Extavia’s Composition and Recombinant Origin

The active component, Interferon Beta-1b, is a recombinant protein manufactured using genetic engineering techniques, specifically by culturing a modified strain of Escherichia coli bacteria. This is a key differentiating factor, as this production method yields a non-glycosylated protein, which structurally distinguishes it from other interferon beta proteins produced in mammalian cell lines.

Extavia is supplied for subcutaneous administration as a lyophilized powder for solution for injection, a form that requires reconstitution with a supplied diluent, typically a Sodium Chloride solution. The powder formulation also contains excipients such as Human Albumin and Mannitol to ensure proper stability and high purity.

How Extavia Functions as an Immunomodulator

Extavia works primarily as an immunomodulator by binding to specific Type I Interferon receptors on the surface of immune cells. This interaction initiates a signaling cascade that helps to regulate the overall immune cell response and their communication networks, confirming its action directly engages with the immune process.

The core purpose of this action is to influence the signals that lead to destructive, chronic inflammation. By encouraging a shift toward an anti-inflammatory state, Extavia offers a sustained intervention aimed at supporting the body’s own regulatory mechanisms and modifying the course of the underlying condition.

What side effects are possible with Extavia?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Extavia (Interferon Beta-1b), based on authoritative government regulatory documents.

Flu-like symptoms, including fever, chills, and muscle aches (myalgia), are classified as Very Common and are most frequently reported during the initial period of treatment, tending to decrease over time. Injection site reactions such as pain, swelling, and redness are also Very Common. Serious tissue damage, known as Injection Site Necrosis (ISN), has been reported.

Safety Classifications and Organ Systems

Adverse events are classified by System Organ Class (SOC):

SOC Category	Very Common / Common Adverse Effects (Examples)
Blood and Lymphatic	Lymphopenia (Very Common), Leukopenia (Common)
Hepatobiliary Disorders	Asymptomatic Increased Liver Enzymes (Very Common)
Nervous System	Headache (Very Common), Dizziness, Hypertonia (Common)
Psychiatric Disorders	Depression, Insomnia (Common)

Serious Adverse Reactions

The official labeling documents rare but serious adverse reactions, including severe Hepatic Injury (e.g., hepatic failure), Anaphylaxis (severe allergic reaction), and Thrombotic Microangiopathy (TMA). Concerns are also noted regarding Congestive Heart Failure and the very rare occurrence of Pulmonary Arterial Hypertension (PAH). Suicidal ideation and suicide attempts have been reported in association with the drug, requiring observation for signs of Depression.

Restrictions and Special Population Notes

The medicine is contraindicated in patients with known hypersensitivity to recombinant or natural interferon beta, Human Albumin, or Mannitol. Caution is advised for use in patients with pre-existing cardiac disease or a history of depression. Initiation of treatment is contraindicated during pregnancy, and safety has not been established in the pediatric population.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Extavia

Overdose Scope	Official Regulatory Statement
Exposure Warning	Taking more than the prescribed dose or taking the dose on two consecutive days has been identified in official labeling as an exposure circumstance requiring immediate action.
Immediate Action Required	The prescribing information instructs users to immediately call their healthcare provider if accidental overexposure occurs. Emergency medical care is required for critical symptoms; contact emergency services (911) if collapse, trouble breathing, or a seizure occurs.
Required Monitoring	Management necessitates laboratory monitoring of complete blood cell counts (CBC), platelet counts, and serum transaminases (liver enzymes) to assess for severe systemic risks.

Documented Severe Manifestations

Severe manifestations that warrant immediate medical attention are the focus of regulatory guidance for potential overexposure:

Anaphylaxis and Severe Allergic Reactions: Signs such as swelling of the face or throat, or difficulty breathing (dyspnea).
Organ System Toxicity: Clinical manifestations suggestive of Thrombotic Microangiopathy (TMA) or Severe Hepatic Injury (e.g., jaundice, abdominal pain, high transaminases).
Neurological Events: New onset or recurring seizures are listed as events requiring prompt attention.
Severe Local Damage: Significant Injection Site Necrosis (severe skin damage) that is ulcerated or rapidly progressing.

Connection to the overall overdose profile: Official regulatory documents define the overdose profile by focusing on the recognition and emergency management of these severe, documented complications like TMA, hepatic failure, and anaphylaxis. This framework mandates that individuals experiencing these life-threatening manifestations must seek immediate medical attention. The recommended procedural step involves supportive treatment and intensive monitoring of hematologic and hepatic function.

Therapeutic Uses of Extavia

What Extavia Treats: Main Uses and Benefits

Extavia is a Disease-Modifying Therapy (DMT) used primarily for the long-term management of active forms of Multiple Sclerosis (MS) in adults. The therapeutic benefit is generally associated with supporting the management of the condition's progression and contributing to easing the disruptive impact of disease activity.

Key Therapeutic Contexts

This medication is commonly used to help manage the frequency of episodic neurological flare-ups (relapses) in conditions like Relapsing-Remitting MS and Active Secondary Progressive MS. The therapy is also relevant for adults with Clinically Isolated Syndrome (CIS)—a first demyelinating event—when the clinical picture is suggestive of the condition.

The focus is on long-term disease modification, which may assist with maintaining functional stability and supports general well-being during symptomatic phases.

“The medication may be part of symptomatic management to help delay the confirmed onset of Clinically Definite Multiple Sclerosis (CDMS).”

Quick Fact: Relief for Episodic Manifestations

Quick Fact: Relief for Episodic Manifestations

Extavia is applied across conditions presenting with acute or disruptive episodes. It supports the patient during difficult episodes by easing distress and is commonly used to help manage the burden of distressing episodic manifestations which may create noticeable physiological strain.

Eligibility and Restrictions for Use

Extavia (interferon beta-1b) is subject to specific regulatory eligibility criteria that define who is permitted to use the medicine and who is formally prohibited.

Contraindicated Populations

Extavia is contraindicated and must not be used in patients with a history of hypersensitivity to natural or recombinant interferon beta, Human Albumin, or any other component of the formulation. The medicine is also contraindicated in patients with current severe depression and/or suicidal ideation and in those with decompensated liver disease.

Age-Group and Data Status

The medicine is generally indicated for use in adults with relapsing forms of Multiple Sclerosis. Safety and efficacy are not established by the FDA for patients under 18 years of age or for those aged 65 years or older. Use in children under 12 years of age is not recommended by the EMA due to a lack of available data.

Conditional Use and Restrictions

Treatment must be used with caution in patients with a history of seizures, pre-existing significant cardiac disease (such as congestive heart failure), or those with previous depressive disorders. Initiation of treatment in pregnancy is contraindicated (EMA); however, the use of Extavia may be considered during pregnancy if clinically necessary. Use during lactation (breastfeeding) should be done with caution.

What should I know about interactions with other medicines?

Extavia (Interferon Beta-1b) has officially documented interaction patterns that primarily relate to additive toxicity and changes in the systemic exposure of co-administered medicines. The use of this medicine is formally contraindicated if there is a known history of hypersensitivity to the active substance, Interferon Beta-1b, or its non-active components, such as Human Albumin.

Documented Interaction Patterns

Additive Pharmacodynamic Risk: Co-administration with known hepatotoxic drugs or alcohol necessitates specific consideration due to the potential for severe hepatic injury. Similarly, combining Extavia with immunosuppressive or myelosuppressive therapies may lead to additive effects on the immune system or bone marrow function. Combining with antiplatelet or anticoagulant agents may also increase the risk of bleeding.

Pharmacokinetic Clearance Modification: Extavia can modify the plasma levels of certain co-administered drugs. For example, official regulatory documents note that Extavia decreases the renal clearance of Zidovudine, resulting in increased systemic exposure to Zidovudine. The metabolism of several other medicines may also be decreased, which can potentially lead to their increased systemic concentrations.

Restrictions and Considerations

Classification	Requirement or Note
Timing-based Rules	No mandatory timing separation rules (e.g., 'must be separated by X hours') are documented.
Population Note	Combined risks, particularly concerning hepatic injury with hepatotoxic agents or alcohol, require greater consideration in patients who already have pre-existing hepatic disease.

Mechanism of Action

Extavia, a recombinant form of Interferon beta-1b, acts as a pharmacodynamic modulator of the immune system. Its mechanism is initiated by binding to the high-affinity Interferon-gamma ( IFN-gamma) receptor complex (IFNAR1/IFNAR2) located on the surface of various cell types, including immune and endothelial cells. This binding triggers the JAK-STAT signaling pathway leading to the phosphorylation of STAT1 and STAT2 transcription factors. The activated STAT proteins dimerize and translocate to the nucleus, modulating the expression of multiple immune-related genes. This intracellular cascade modifies the balance of pro- and anti-inflammatory cytokines, reduces the proliferation and activation of CD4^+ T cells, and decreases the migration of inflammatory leukocytes across the blood-brain barrier (BBB). These actions result in system-level physiological modulation of the cellular immune response and influence neuronal trophic factor activity

Dosage and Administration Information

The administration of Extavia (interferon beta-1b) must be guided by a healthcare professional, with patients or caregivers receiving formal training in subcutaneous injection technique.

Official Administration Schedule

Dosing Rule	Detail
Route of Administration	Subcutaneous injection (under the skin).
Recommended Maintenance Dose	0.25 mg (1.0 mL of reconstituted solution) injected every other day.
Dose Titration	Treatment must start with a lower dose of 0.0625 mg (0.25 mL) every other day, with a gradual increase over a six-week period until the full 0.25 mg dose is reached.
Frequency and Timing	Injected every other day. The next dose should be given approximately 48 hours after the previous dose.
Age-Specific Use	Approved for adults and adolescents aged 12 to 17 years at the adult dose; use is not recommended in children under 12 due to lack of data.

Preparation and Procedure

Extavia is supplied as a lyophilized powder and must be reconstituted with 1.2 mL of the supplied diluent (0.54% Sodium Chloride Solution). The vial must be gently swirled until the powder is fully dissolved; do not shake. The reconstituted solution should be visually inspected for particulate matter and discoloration before use.

When administering, patients must rotate the injection sites to minimize the risk of severe reactions. Analgesics and/or antipyretics may be used concurrently on treatment days to help ameliorate flu-like symptoms.

Missed Dose Instructions

If a dose is missed, the patient should take it as soon as they remember, or are able to take it. The patient must not take Extavia on two consecutive days. The subsequent injection must then be scheduled approximately 48 hours (two days) after that replacement dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Extavia

Evidence for Use in Relapsing-Remitting Multiple Sclerosis (RRMS)

Research has explored the use of Extavia (Interferon Beta-1b) in Relapsing-Remitting Multiple Sclerosis (RRMS) using major randomized, controlled trials (RCTs). These studies were applied in cohorts of adults with established RRMS who were experiencing clinical activity. Researchers used these trials to examine short-term and intermediate-term changes, primarily focusing on outcomes describing episodic or acute changes and outcomes reflecting daily functioning or activity level. Studies monitored patterns related to relapse frequency measurements in the treated groups compared to control groups over the typically two-year study durations. Radiological assessments observed patterns related to lesion measurements on MRI scans. Limited information for long-term outcomes was available regarding sustained changes in disability status as measured by the Expanded Disability Status Scale (EDSS) from the initial controlled trials.

Evidence for Use in Clinically Isolated Syndrome (CIS)

Research has also explored the use of Extavia in adults who have experienced a first demyelinating event, known as Clinically Isolated Syndrome (CIS). These studies used dedicated randomized, controlled trial designs to examine participants with CIS who had supporting evidence on their MRI scans. The primary outcome monitored in these research scenarios was the time until the conversion to Clinically Definite Multiple Sclerosis (CDMS). Controlled trials monitored patterns related to the time before participants converted to a confirmed CDMS diagnosis when compared to control groups. Existing studies provide limited insight into outcomes related to long-term disability in individuals with CIS many years after the initial intervention.

Research Gaps and Unresolved Questions

A key area where certainty remains low is the influence of Neutralizing Antibodies (NAbs) on the measured long-term outcomes. While NAb development was observed in some studies, the full impact on sustained clinical outcomes continues to be a subject of ongoing research and analysis. Furthermore, there is limited information for long-term outcomes from controlled trial data, as follow-up durations were limited in the initial studies. Data for certain groups remain insufficient, and evidence is limited regarding the use of the medicine in specific subgroups of older adults or patients with complex comorbid conditions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Extavia (FAQ)

Q: What exactly is the purpose of Extavia in treating multiple sclerosis (MS)?

A: According to official regulatory documents, the medicine's primary purpose is to help reduce the frequency of clinical exacerbations (relapses) in patients with relapsing forms of multiple sclerosis. The medicine is classified as a disease-modifying therapy, which suggests an intention to influence the underlying biological processes.

Q: Is Extavia considered a cure for multiple sclerosis?

A: Extavia is classified as a Disease-Modifying Therapy (DMT). This means it is intended to alter the underlying biological processes of the chronic condition, and it is not considered a cure for multiple sclerosis.

Q: Can Extavia help slow down the progression of physical disability in MS?

A: Studies and official information indicate that the medication is intended to help slow MS disease progression. This action is consistent with the intention to delay the accumulation of irreversible neurological damage, which is associated with long-term disability.

Q: Why is Extavia sometimes used for people who have only had a clinically isolated syndrome (CIS)?

A: Official research has explored the use of Extavia in people who have experienced a Clinically Isolated Syndrome (CIS), which is a first episode of MS-like symptoms. Treatment in this population is intended to delay the time until the condition converts to a confirmed diagnosis of Clinically Definite Multiple Sclerosis (CDMS).

Q: How does Extavia specifically reduce the number of relapses?

A: Extavia works as an immunomodulator by binding to receptors on immune cells. This action helps to regulate the immune cell response by balancing pro- and anti-inflammatory signals. The interaction also appears to influence the migration of inflammatory cells across the blood-brain barrier (BBB), which may help modulate the inflammatory response in the central nervous system.

Q: What is the difference between Extavia and its other brand name version, Betaseron?

A: Extavia and Betaseron are considered identical products. Both contain the same active ingredient, Interferon Beta-1b, and are approved for use in treating multiple sclerosis.

Q: What is the difference between Extavia and other interferon treatments for MS?

A: Extavia (Interferon Beta-1b) is a non-glycosylated protein, meaning it lacks certain sugar molecules. This structural difference distinguishes it from other interferon beta proteins manufactured using different methods.

Q: How long has Extavia been approved and used for MS treatment?

A: According to regulatory records, Extavia was first approved by the U.S. Food and Drug Administration (FDA) on August 14, 2009, for the treatment of multiple sclerosis.

Q: How long do the flu-like symptoms from the injections typically last?

A: Flu-like symptoms are a very common adverse reaction, particularly at the start of treatment. Official information indicates these symptoms often resolve within approximately 24 hours after the injection, though they may be reported as intermittent.

Q: Is it true that the flu-like symptoms can get better over time while using Extavia?

A: Yes. Official documents describe that these symptoms are most frequent during the initial period of treatment and tend to decrease over time as the body adjusts to the medication.

Q: What are the common injection site reactions I should expect from Extavia?

A: Injection site reactions are very common. These reactions typically include pain, swelling, and redness at the site of the injection.

Q: What should I watch out for with injection site necrosis?

A: Injection site necrosis (serious tissue damage) is a reported side effect. Signs of a serious problem may include swelling and pain, draining fluid, infections that do not heal, or skin breaks that may have blue-black discoloration.

Q: What is the risk of lipoatrophy with long-term use of Extavia?

A: Loss of fatty tissue beneath the skin, known as lipoatrophy, has been observed in some patients using the medication. This side effect has been observed in patients, particularly in connection with long-term use at the injection sites.

Q: What is the risk of developing neutralizing antibodies to Extavia over time?

A: The development of neutralizing antibodies (NAbs) has been observed in some clinical studies of the medication. The full impact of these antibodies on long-term clinical outcomes continues to be a subject of ongoing research.

Q: Can I continue taking Extavia if I become pregnant?

A: Initiation of treatment with Extavia is contraindicated (must not begin) during pregnancy. However, if already on the medicine, treatment continuation is determined to be clinically necessary by a healthcare professional.

Q: Is it safe to drink alcohol while taking Extavia?

A: Regulatory documents state that co-administration of Extavia with alcohol requires specific caution. This is due to the potential for additive risk of severe hepatic injury (liver damage).

Q: Can a patient with a history of severe depression use Extavia?

A: Extavia is contraindicated (must not be used) in patients with current severe depression and/or suicidal ideation. However, regulatory guidance indicates that caution is advised for use in patients with a history of depressive disorders.

How should Extavia be stored and disposed of?

The official storage requirements for Extavia are separated for the unmixed powder and the reconstituted solution.

Storage Conditions

Product State	Temperature Requirement	Stability Constraint
Lyophilized Powder	Store at room temperature (20 C to 25 C).	May be stored up to 3 months between 15 C and 30 C.
Reconstituted Solution	Refrigerate at 2 C to 8 C.	Must be used within three hours of mixing; Do not freeze.

The medication must be kept out of the reach of children.

Disposal Instructions

Extavia is a single-use vial, and any unused solution must be discarded. Used needles, syringes, and vials must be disposed of in a closeable, puncture-resistant sharps container. Do not place used sharps in household trash or recycling; follow all state and local regulations for final sharps container disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.